AD/PD 2022 and Biomarkers View overview page

5:03
ADNI: developing biomarkers for Alzheimer’s disease
Michael Weiner • 16 Mar 2022
3:45
Novel probe for selective imaging of tau tangles in human retina
Silvia Di Angelantonio • 18 Mar 2022
0:50
Lymphatic system as a source of disease-specific biomarkers
Laura Santambrogio • 18 Mar 2022
5:45
Plans to reduce sampling bias in the ADNI project
Michael Weiner • 16 Mar 2022
2:05
Developments on microglia in neuroinflammation: TREM2 upregulation in Alzheimer’s disease
Greg Lemke • 18 Mar 2022
1:50
Strengthening diversity in dementia biomarkers research
Pamela Lukasewicz Ferreira • 16 Mar 2022
1:50
Advances in Alzheimer’s disease biomarkers & therapies
Stephen Pasternak • 16 Mar 2022
2:48
Biomarkers for Alzheimer’s disease in a preclinical setting
Nicholas Ashton • 18 Mar 2022
1:46
Challenges in the clinical implementation of Alzheimer’s disease biomarkers
Charlotte Teunissen • 17 Mar 2022
1:45
The use of Alzheimer’s disease plasma biomarkers in the clinic: further research needed
Pamela Lukasewicz Ferreira • 16 Mar 2022
1:02
Differences between Alzheimer’s disease biomarkers: p-Tau181, p-Tau231 & p-Tau217
Nicholas Ashton • 18 Mar 2022
1:28
Impact of blood-based biomarkers on Alzheimer’s disease treatments
Charlotte Teunissen • 17 Mar 2022
1:45
The accuracy of plasma biomarkers for Alzheimer’s disease outside of a controlled setting
Nicholas Ashton • 18 Mar 2022
2:11
Upcoming plasma biomarkers for Alzheimer’s disease: Aβ, p-tau and GFAP
Pamela Lukasewicz Ferreira • 16 Mar 2022
3:35
The MIRIADE training program: development of dementia biomarkers
Charlotte Teunissen • 17 Mar 2022
1:23
Plasma biomarkers for Alzheimer’s disease as pre-screening tools
Nicholas Ashton • 18 Mar 2022
The content of VJDementia is intended for healthcare professionals